Fc Engineered Anti-Human CD20 Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ03] (CAT#: BioBet-C003ZP) Datasheet

Target
CD20
Isotype
Human Antibody
Description
CDC-enhanced Ofatumumabis a Fc-modified anti-CD20 therapeutic biobetter. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Ofatumumab, the Fc region of Ofatumumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Chronic lymphocytic leukaemia
Phase IIIB-cell lymphoma
Diffuse large B cell lymphoma
Follicular lymphoma
Multiple sclerosis
Phase II Marginal zone B-cell lymphoma
Precursor cell lymphoblastic leukaemia-lymphoma
Classification
Therapeutic antibody; biobetter
Patent
Date of FDA Approval (Patent Expiration): 2009 (2023)
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop CDC-enhanced Ofatumumab. For commercial partners interested in our CDC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
MS4A1
Full Name
membrane spanning 4-domains A1
Background
This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein.
Alternative Names
B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16
Gene ID
UniProt ID
Trade name
Arzerra
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB06650
CAS number
679818-59-8
Antibody Isotype
Human IgG1
Description
Ofatumumab is the first human monoclonal antibody targeting the CD20 molecule approved by the FDA in 2014 for the treatment of refractory chronic lymphocytic leukemia. It appears to inhibit the activation of early B lymphocytes, showing potential for treating follicular lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing multiple sclerosis. This antibody can be used in patients with refractory CLL.
Indication
Chronic lymphocytic leukaemia
Phase IIIB-cell lymphoma
Diffuse large B cell lymphoma
Follicular lymphoma
Multiple sclerosis
Phase II Marginal zone B-cell lymphoma
Precursor cell lymphoblastic leukaemia-lymphoma
Synonyms
HuMax-CD20
Ofatumumab
Ofatumumabum
UNII
M95KG522R0

Ofatumumab is an anti-CD20 human monoclonal antibody that binds unique epitopes on CD20 with high specificity. CD20 antigen is expressed only on B-cell lymphocytes. CD20 antigen is expressed only on B-cell lymphocytes. Compared to rituximab, ofatumumab binds more tightly to CD20 and has a lower shut-down rate. It causes cytotoxicity in cells expressing CD20 through complement-dependent cytotoxicity (ADCC) and antibody-dependent cytotoxicity (CDC).
Blood cancers
Chronic Lymphocytic Leukaemia (CLL)
Chronic Lymphocytic Leukemia (CLL) - Refractory
Autoimmune diseases
Rheumatoid Arthritis
Solide Tumors
Multiple Sclerosis

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *